ArticleEuropean heart journal. Digital health2025
Liquid biopsy based on whole blood transcriptome and artificial intelligence for the prediction of coronary artery calcification: a pilot study.
Article in European heart journal. Digital health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Whole blood RNA expression is modulated in response to signals from tissues, including the vessel wall. The primary objective of this study was to explore the ability of whole blood transcriptomes, analysed using artificial intelligence (AI), to predict coronary artery calcifications (CAC). Methods and results: A total of 196 subjects [men aged 40-70 years and women aged 50-70 years without known cardiovascular disease (CVD)] were non-consecutively enrolled for CAC assessment via chest computed tomography. Whole blood RNA was isolated and sequenced. Different AI models were trained using clinical and transcriptomic variables as distinctive features to identify the presence of CAC (Agatston score >0). Finally, we compared the predictive performance of these models. The prevalence of CAC was 43.9%. The combined AI model, incorporating transcriptome data along with age, sex, body mass index, smoking status, diabetes, and hypercholesterolaemia, achieved an area under the curve (AUC) of 0.92 (95% CI, 0.88-0.95) for predicting the presence of CAC, with a sensitivity of 92%, specificity of 80%, positive predictive value of 81%, negative predictive value of 91%, and an overall accuracy of 86%. The combined AI model demonstrated significantly improved discrimination compared with the transcriptomic model (AUC 0.79; Conclusion: In this pilot study, an AI model integrating whole blood transcriptome data with clinical risk factors demonstrated the ability to predict CAC, providing incremental value over clinical models. Further studies are needed to achieve more robust validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.